Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00266786




Registration number
NCT00266786
Ethics application status
Date submitted
16/12/2005
Date registered
19/12/2005
Date last updated
8/02/2017

Titles & IDs
Public title
Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery
Scientific title
A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery
Secondary ID [1] 0 0
ROX 2005-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Postoperative Pain 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Intranasal Ketorolac Tromethamine
Treatment: Drugs - Intranasal Placebo

Experimental: Intranasal Ketorolac Tromethamine -

Placebo comparator: Intranasal Placebo -


Treatment: Drugs: Intranasal Ketorolac Tromethamine
Intranasal at 30mg

Treatment: Drugs: Intranasal Placebo
Intranasal Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Summed Pain Intensity Difference (SPID) on Day 1
Timepoint [1] 0 0
6 hours after drug administration
Secondary outcome [1] 0 0
Pain intensity difference scores
Timepoint [1] 0 0
Prior to receiving study drug and at 20, 40, and 60 minutes, and 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours after the first dose, then prior to each dose up to 72 hours
Secondary outcome [2] 0 0
Quality of analgesia
Timepoint [2] 0 0
Prior to receiving study drug and at 20, 40, and 60 minutes, and 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours after the first dose, then prior to each dose up to 72 hours
Secondary outcome [3] 0 0
Global assessment of pain control
Timepoint [3] 0 0
8 hours following first dose of study medication
Secondary outcome [4] 0 0
Morphine sulfate consumption at 24, 48, and 72 hours
Timepoint [4] 0 0
24, 48, and 72 hours after drug administration

Eligibility
Key inclusion criteria
* Men or women age 18 through 64 years
* Major abdominal surgery
* Body weight = 100 and = 300 pounds
* Negative serum pregnancy test
* Pain intensity score at least 40 (moderate pain) on 100 mm visual analog scale
* Minimum 48 hour hospital stay and 5 day maximum stay
* Able to provide written informed consent
* Willing and able to comply with all testing requirements of the protocol
Minimum age
18 Years
Maximum age
64 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Allergy or sensitivity to ketorolac or ethylene diamine tetraacetic acid (EDTA)
* Allergy or significant reaction to opioids
* Allergic reaction to aspirin or other nonsteroidal anti-inflammatory drug (NSAIDs)
* Current upper respiratory tract infection or other respiratory tract condition that could interfere with absorption of the nasal spray or adverse event assessment
* Use of any intranasal product in past 24 hours
* Clinically significant abnormality on screening lab tests
* History of cocaine use
* Active peptic ulcer disease or significant history of peptic ulcer disease or gastrointestinal bleeding
* Advanced renal impairment or risk for renal failure
* History of other medical problems that could interfere with the study participation
* Pregnancy or breastfeeding
* Participation in another investigational study within past 30 days

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
321
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
New Zealand
State/province [3] 0 0
Hamilton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Egalet Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lincoln Bynum, MD
Address 0 0
ICON Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00266786